Ma Iune 6, ua paʻi ka puke pai lapaʻau honua ʻo Journal of Hematology & Oncology i nā hopena noiʻi pae I/II (KL264-01/MK-2870-001) o ka TROP2 ADC sacituzumab tirumotecan (sac-TMT) hou ma ke ʻano he monotherapy no nā ʻōpū paʻa kūloko holomua a metastatic paha i kū ʻole i nā lāʻau lapaʻau maʻamau.
ʻO Sacituzumab tirumotecan (sac-TMT) kahi hui antibody-drug i haku ʻia me kahi antibody monoclonal anti-TROP2 i hoʻopili ʻia i kahi mea hoʻopaʻa topoisomerase I i loaʻa mai ka belotecan cytotoxic (KL610023) ma o kahi mea hoʻopili hou.
Nā ʻAno Hana
Loaʻa i nā maʻi nā ʻōpū paʻa kūloko holomua/metastatic i hiki ʻole ke ʻoki ʻia i nā lāʻau lapaʻau maʻamau. I loko o nā hui dose-escalation pae 1, loaʻa i nā maʻi nā ʻōpū paʻa kūloko holomua/metastatic i hiki ʻole ke ʻoki ʻia i nā lāʻau lapaʻau maʻamau. Ua lawelawe ʻia ʻo Sac-TMT ma o ka lawelawe intravenous i kēlā me kēia 2 pule ma 2 a 12 mg/kg. I ka pae 2, ua loaʻa i nā maʻi me TNBC a me HR+/HER2− ka maʻi ʻaʻai umauma sac-TMT e like me nā dosis i ʻōlelo ʻia no ka hoʻonui ʻana (RDEs) i ʻike ʻia i ka pae 1. ʻO nā pahuhopu mua ka hoʻoholo ʻana i ka nui o ka lāʻau i ʻae ʻia (MTD) o sac-TMT a me ka hoʻokumu ʻana i nā RDE (pae 1) a me ka hoʻoholo ʻana i ka ORR e like me RECIST v1.1 e ka loiloi mea noiʻi (pae 2). Ua loiloi ʻia nā hanana ʻino e like me ka mana NCI-CTCAE 5.0.
Nā Hualoaʻa
He kanakolu mau maʻi i kākau inoa ʻia i ka pae 1 a loaʻa iā lākou ka sac-TMT 2 mg/kg (n = 4), 4 mg/kg (n = 7), 5 mg/kg (n = 7), 5.5 mg/kg (n = 5), a me 6 mg/kg (n = 7). ʻElima mau maʻi i loaʻa nā ʻawaʻawa palena lāʻau: stomatitis papa 3 ma 4, 5.5, a me 6 mg/kg; ʻulaʻula papa 3 ma 5 mg/kg; a me ka urticaria papa 3 ma 6 mg/kg. ʻO MTD he 5.5 mg/kg a ʻo RDE he 4 a me 5 mg/kg. I ka hoʻonui ʻana o ka pae 2, ʻo ORR (95% CI) he 34.8% (16.4%, 57.3%) i ka hui 4-mg/kg (n = 23) a me 38.9% (23.1%, 56.5%) i ka hui 5-mg/kg (n = 36) no TNBC. ʻO ORR (95% CI) he 31.7% (18.1%, 48.1%) no ka maʻi ʻaʻai umauma HR+/HER2− (n = 41).
Nā hopena
Ua hōʻike ʻo Sac-TMT i kahi ʻikepili palekana hiki ke hoʻokele ʻia i nā poʻe maʻi me nā ʻōpū paʻa kūloko holomua/metastatic hiki ʻole ke ʻoki ʻia a me ka hana antitumor e hoʻohiki ana i ka metastatic TNBC a me HR+/HER2 − maʻi ʻaʻai umauma. Ke noiʻi ʻia nei ʻo Sac-TMT ma nā haʻawina pae 3.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Ka manawa hoʻouna: Iune-19-2025